Translational Study of MSS, TP53 Mutation and Chromosome Instability Relationship in Endometrial Carcinoma

Launched by PEKING UNION MEDICAL COLLEGE HOSPITAL · Jul 22, 2024

Keywords

ClinConnect Summary

This clinical trial is designed to explore the relationship between specific genetic changes (like the TP53 mutation) and chromosome instability in endometrial cancer, which is a type of cancer that affects the lining of the uterus. Researchers want to understand how these changes might influence a patient's prognosis, or outlook, after diagnosis. To do this, they will collect small samples of tumor tissue from participants and analyze them to gather important information about the cancer.

To be eligible for this study, participants need to be women aged 18 or older who have been diagnosed with endometrial cancer, confirmed by a medical professional. They also need to agree to participate and sign consent forms. Those who have received certain cancer treatments recently or have specific prior conditions will not be able to participate. If you join the study, you can expect a follow-up call after your surgery to gather more information about your health and the progress of your condition. This trial is not yet recruiting participants, but it aims to provide valuable insights into the nature of endometrial cancer and help improve future treatments.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • willing to participate in the study and sign the informed consent
• • age ≥18 years old
• • researchers evaluated that it was suitable to participate in this translational study
• • Endometrial cancer was confirmed histologically
• • histopathological molecular classification was consistent with pMMR type and POLE wild type
• • The tumor tissue obtained by operation was the primary lesion
• Exclusion Criteria:
• • Received chemotherapy within 14 days prior to sample collection, or received anti-tumor drug therapy such as radiotherapy, biotherapy, endocrine therapy, targeted therapy, immunotherapy, within 21 days prior to sample collection
• • previously treated with KIF18A inhibitors
• • researchers believed that the subjects were not suitable for the translational study for other reasons